Kevin R. Holme - Concepedia

Author

Kevin R. Holme

Also Known As

Holme, Kevin R., K Holme, K. Holme, K. R. HOLME, K. R. Holme, K.R. Holme, KEVIN R. HOLME, Kevin Holme, Kevin R Holme, Kevin R. Holme

Publications

2.3K

Citations

H-Index

112

Concepts

All Affiliations

McGill University Oregon Health & Science University Brigham and Women's Hospital Aptose Biosciences (United States)Michigan State University

About

Kevin R. Holme is an author at McGill University specializing in medicine, biochemistry, and glycobiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	1.3K
2	Engineering	7	7	345
3	Health Sciences	2	2	257
4	Business	1	1	10
5	Management	1	1	10

Kevin R. Holme

Publications

Citations

H-Index

Page 1

	Year	Citations
Biologically meaningful determinants of the in vitro strength of lumbar vertebrae A. Vesterby, Li. Mosekilde, H.J.G. Gundersen, Bone MechanobiologyLumbosacral RadiculopathyLumbar SpineKinesiologyDegenerative Spine	1991	234
Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. Michael R. Wessels, Lawrence C. Paoletti, Dennis L. Kasper, Journal of Clinical Investigation Polysaccharide-protein Conjugate VaccineHumoral ResponseImmunologyGlycobiologyPolysaccharide	1990	191
Chitosan N-sulfate. A water-soluble polyelectrolyte Kevin R. Holme, Arthur S. Perlin Carbohydrate Research Chitosan N-sulfateEngineeringPolysaccharidePolymer ChemistryPolymers	1997	161
Matrix Metalloproteinase Inhibitors: A Structure−Activity Study Daniel E. Levy, France Lapierre, Weisheng Liang, Journal of Medicinal Chemistry Protein ChemistryMatrix Metalloproteinase InhibitorBiochemistryAmino AcidNatural Sciences	1998	141
Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties France Lapierre, Kevin R. Holme, Lun Lam, Glycobiology	1996	133
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity <i>in vivo</i> Sean G. Buchanan, J. Hendle, Patrick S. Lee, Molecular Cancer Therapeutics Gene AmplificationAntitumor ActivityChemoprevention StrategyExquisite SelectivityCancer Biology	2009	130
Modulation of Nonspecific Binding in Ultrafiltration Protein Binding Studies Kyoung‐Jin Lee, Rachel Mower, Tom Hollenbeck, Pharmaceutical Research	2003	128
Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor Masayuki Ishihara, Patrick N. Shaklee, Zicheng Yang, Glycobiology GlycobiologyHeparin-derived OligosaccharidesPolysaccharideChemical BiologyAngiogenesis	1994	94
Identification of Structural Features of Heparin Required for Inhibition of Herpes Simplex Virus Type 1 Binding Betsy C. Herold, Susan I. Gerber, Tamar Polonsky, Virology Structural FeaturesVirus StructureHeparin RequiredMolecular VirologyProtein Folding	1995	91
SGX393 inhibits the CML mutant Bcr-Abl <sup>T315I</sup> and preempts <i>in vitro</i> resistance when combined with nilotinib or dasatinib Thomas O’Hare, Christopher A. Eide, Jeffrey Tyner, Proceedings of the National Academy of Sciences	2008	79

Page 1